

House dust mite allergy: environment evaluation and disease prevention

Sheng-Jie Yu^{1,2}, En-Chih Liao^{3,4,5} and Jaw-Ji Tsai^{1,2,6,*}

¹Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40705, Taiwan

²Section of Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan

³Center for Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan

⁴Department of BioIndustry Technology, Da Yeh University, Changhua 51591, Taiwan

⁵Department of Medical Technology, Jen Ten College of Medicine, Nursing and Management, Miaoli 35664, Taiwan

⁶Institute of Clinical Medicine, National Yang Ming University, Taipei 11221, Taiwan

There are two groups of dust mites, house dust mites (HDMs) and storage mites (SMs), that have been identified in the household environment. Both could induce airway inflammation through activation of innate and adaptive immunity and lead to asthma. In order to monitor environmental dust mite infestation, different methods can be used to detect their presence, such as the use of floating methods, monoclonal antibodies, and nanostructured biosensor. SM could be identified in the storage room, mainly in contaminated food such as mushrooms and corn starch. In HDM-sensitive subjects and mice that were challenged with HDM or SM after sensitization, these mites could up-regulate IgE levels, T helper 2 associated cytokine production and airway hypersensitivity. Different age groups of subjects were sensitized by different species of mites. More subjects above 70 years were sensitized by SM and more subjects below the age of 40 years were sensitized to HDM. Different allergenic components of dust mite extracts, such as Der p 1, Der p 2, could activate innate immunity through activating pattern recognition receptor (PRR) and then lead to allergic inflammation. The best modality to treat HDM allergy is immunomodulation through Treg cells and IgA production. In the recent years, many studies indicated probiotics could increase IgA secretion and the number of Treg cells. However, some studies conducted in adults have contradictory effects in reducing allergic symptoms. Therefore, probiotics confer inconclusive benefits on the allergic symptoms.

Key words: House dust mite; Allergic rhinitis; Innate immunity; Probiotics

Correspondence: Jaw-Ji Tsai

Section of Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard, Sec. 4, Taichung 40705, Taiwan

E-mail: jawji@vghtc.gov.tw

Tel: +886-4-23592525 (ext 3013)

Fax: +886-4-23592705

Received: September 7, 2014

Accepted: October 14, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution. Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Asthma is a disease characterized by chronic airway inflammation, and the cause of inflammation is driven by gene and environment interactions. Although these interactions may be affected by many environmental factors, the most important environmental factors are indoor allergens of dust mite and outdoor air pollutants. Both risk factors may trigger the inflammation independently or synergistically. The successful identification of environmental allergens and avoidance of pollutants may be effective to prevent allergen marching and disease exacerbation.

HDM ALLERGY: ENVIRONMENTAL EVALUATION

There are many species of dust mites infested in and around the houses worldwide. The two most common house dust mites (HDMs) are *Dermatophagoides pteronyssinus* (Dp) and *Dermatophagoides farina*. Two common storage mites (SMs) are *Blomia tropicalis* (Bt), *Turophapus putrescentias* (Tp) [1-3].

HDM CAN BE IDENTIFIED IN THE HOUSEHOLD USING DIFFERENT METHODS

We used the floating method to identify the types of mites from houses of mite-allergic patients. The results showed that Dp accounted for 52.1% of the total number of mites and was found in every residence. Bt accounted for 44.3% of the total number of mites. We also demonstrated high prevalence of sensitization to Bt in Taiwan [4]. We used a series of recombinant allergenic components of Bt for specific IgE measurement. As well, Bt crude extracts were used for skin tests. We found that 44% of asthmatic patients were allergic to Bt. Furthermore, 43% of these Bt-allergic patients were also allergic to Blo t 5 [5]. A high prevalence of Bt sensitization was detected in asthmatic patients. However, 18% of these patients were caused by cross reactivity between Dp and Bt. In order to facilitate the analysis of IgE specific to Der p 2, the major allergen in Dp, we raised a panel of monoclonal antibodies (MoAbs) to Der p 2 antigens. We used MoAbs to purify major allergen Der p 2 from HDM extracts, and used the purified Der p 2 in skin tests and serology tests. The results showed that 90% of

the patients' skin reacted to Der p 2 and their serum contained Der p 2-specific IgE. Thus, we demonstrated the incidence of Der p 2 hypersensitivity in asthmatic patients [6]. Furthermore, we can use these MoAbs to calculate the mite numbers in the dust by quantifying the concentration of Der p 2. In the most recent survey from April 2010 to March 2011 conducted by medical centers in central Taiwan, the numbers of mites in the carpets and mattresses were different [7]. There are a significantly higher number of mites in the mattresses than in the carpets. The number of mites also fluctuates with season, with the highest number of mites in the summer (Fig. 1). In the recent years, a novel technology has been discovered to identify environmental mite allergens. A highly sensitive nanostructured biosensor, including a three-dimensional (3D) sensing component with uniformly deposited gold nanoparticles, was used to detect Der p 2. The detection limit of the 3D gold nanoparticle-based biosensor was 1 pg/mL and the dynamic range was 5 µg/mL (Fig. 2). The novel nanostructured biosensor could be useful for fast detection of environmental allergens [8].

EXPOSURE TO HDM CAN CAUSE ALLERGIC RESPONSES IN THE AIRWAY OF BOTH HUMANS AND MICE

Dust mite can induce airway inflammation: In the allergic sensitization phase, dendritic cells (DCs) play an important role by acting as professional antigen presenting cells in the allergic airway inflammation [9, 10]. After the desquamation of epithelial




Fig. 1. Number of house dust mites isolated from mattresses and carpets from April 2010 to March 2011.

cells and the disruption of tight junction caused by HDM, DCs can identify and process the antigens, and then present these antigens on the major histocompatibility complex class II molecules to naive T lymphocytes in local lymph nodes. This in turn induces cascades of the T helper 2 (Th2)-immune allergic inflammatory processes [10-12]. In the Dp-allergic subjects who were intranasally challenged with Dp extracts, both the immediate and late phases of allergic response were observed. HDM extracts could induce nasal symptoms by increasing nasal resistance [13]. When subjects were intranasally administrated with HDM extracts in animal study, a chronic airway inflammation was up-regulated [14]. Similar report showed that inhalation of HDM extracts significantly increased the recruitment of eosinophils and a substantial number of neutrophils, macrophages and lymphocytes [15]. With the characteristics of mixed eosinophilic and neutrophilic inflammation, the HDM mouse model becomes an interesting animal model that may closely reflect the situation of allergic asthma in humans [16].

IDENTIFICATION OF SM IN KITCHENS AND ITS CORRELATION WITH ALLERGIC DISEASES

SM has been reported to induce anaphylaxis through the consumptions of mite-contaminated food [17]. Based on its




Fig. 2. Schematic drawing of different detection methods with different sensitivity. (A) Flat chamber coated with detection monoclonal antibodies (MoAb). (B) Concave chamber with Au thin film as electrode then coated with MoAb. (C) Concave chamber with Au nanoparticle thin film as electrode then coated with MoAb.

allergenic potential and abundance, the storage mite Tp is a major cause of allergic asthma and allergic rhinitis. Tp is found worldwide, mainly in contaminated food such as mushrooms, wheat flour, wheat germ, animal chow, and cereal (Table 1) [18]. Tp-induced allergy is mostly reported as occupational exposure among farmers, grain workers, bankers, and food industry workers, and is considered closely associated with respiratory diseases in these individuals [19].

EXPOSURE TO SM CAUSES AIRWAY INFLAMMATION IN MOUSE ANIMAL MODEL

Tp, a kind of SM, has been shown to induce allergic symptoms such as bronchial asthma, allergic rhinitis, conjunctivitis, and atopic dermatitis [20, 21]. In recent years, storage mites have been reported to be the key allergenic components of dust samples worldwide, thus highlighting their clinical significance [22].

In animal models, Balb/c mice were intraperitoneally sensitized with Tp and then intratracheally challenged with Tp. The airway inflammation was analyzed by airway hypersensitivity to methacholine and bronchial alveoli lavage immune responses to Tp were analyzed by immunoglobulin and cytokines measurements.

When Balb/c mice were challenged with different concentration of Tp (10 µg/µL and 40 µg/µL), there existed a dose-dependent increase of Tp-specific IgE and IgG1 in the sera. In addition, the inflammatory cell infiltration was up-regulated in the airway. Not only were the eosinophils and neutrophils increased, but the levels of Th2 cytokines, interleukin (IL) 4, IL-5, and IL-13 were also increased in the bronchial alveolar lavage fluid in the Tp-sensitized mice. This airway inflammation was associated with airway hypersensitivity to methacholine and the reverse of Th1/Th2 subpopulation in the blood. When the lung tissue was analyzed for the proinflammatory cytokine IL-6/IL-17F and transcription factor GATA-3, their levels were all elevated (Table 2) [23].

Table 1. Identification of *Turophapus putrescentias* in different food products

	Mushrooms	Wheat flour	Wheat germ	Animal chow	Rice
Positive rate (%)	33.3	12.5	6.5	53.3	0

DIFFERENT AGE GROUPS OF SUBJECTS SENSITIZED BY DIFFERENT SPECIES OF HDM & SM

A previous study demonstrated that Dp is highly prevalent in Taiwan, where the climate is subtropical [24]. More than 80% of asthmatic patients are allergic to Dp as determined by skin tests and specific IgE measurements [25]. Dp and Tp have been demonstrated to be related to allergic diseases [24, 26]. Although Tp can cause allergic respiratory symptoms after occupational exposure in farms and grain elevator stores, a lot of attention is currently being paid to its allergenicity in nonoccupational environments [27].

There is a high prevalence of Tp sensitization in general adult populations in both Europe [27] and Asia [28]. In Spain, HDM-allergic patients also show a very high prevalence (73–83%) of storage mite sensitization [28]. Fifty-two percent of adult individuals over the age of 50 are sensitive to Tp, which is much more prevalent than Dp sensitization in the same age group (22%).

Similar findings have been reported in Korea [29].

Subjects of different age groups were compared for their dust mite specific IgE in the sera. There were more subjects sensitized by Tp than Dp in the subjects over the age of 70 years. The association between age and sensitization to dust mites was different; there were more subjects below the age of 40 who were sensitized to Dp, and more subjects over the age of 70 that were sensitized to Tp (Table 3). The clinical relevance of mite sensitivity in elderly subjects with chronic obstructive pulmonary disease (COPD) was also analyzed. The results showed that, among the 63 elderly subjects, 50 (79.3%) had COPD. Among the 50 subjects with COPD, 38.0% (19/50) were Tp-sensitive subjects and 14.0% (7/50) were Dp-sensitive subjects [29]. All of the Dp-sensitive subjects were also Tp-sensitive. The results showed that the elderly subjects with COPD had a higher prevalence of sensitivity to Tp than to Dp, and the IL-8 level was significantly increased in allergic COPD patients (Table 4) [30].

Table 2. Systemic and circulative immune responses to Tp extracts

Variable		Normal saline	Tp 10 µg/mL	Tp 40 µg/mL
IgE*	↑	0.22	0.35	0.53
IgG1*	↑	0.25	0.51	1.12
IgG2a*	–	0.21	0.23	0.22
AHR (Penh)†	↑	1.98	3.01	4.68
Eosinophils in BALF‡	↑	2.01	20.12	51.23
Neutrophils in BALF‡	↑	3.51	6.87	27.22
IL-4 in BALF§	↑	7.23	23.51	122.21
IL-5 in BALF§	↑	14.24	48.45	151.29
IL-13 in BALF§	↑	24.58	52.45	134.21
Th1/Th2 ratio	↓	1.01	0.84	0.70

Tp, *Tuorhaphus puterscentias*; AHR, airway hyperresponsiveness; BALF, bronchoalveolar lavage fluid; IL, interleukin.

*The absorbance of optical density at 405 nm. †Response at a concentration of 25-mg/mL methacholine. ‡No. of cells $\times 10^4$ /mL. §Cytokine concentration (pg/mL).

Table 3. Difference of mites' sensitization between age over 70 years and below 40 years in allergic subjects

	Over 70 years (n=112)	Below 40 years (n=87)	p-value
Allergic to Tp	44 (39.3)	16 (18.4)	0.003
Allergic to Dp	25 (22.3)	25 (28.7)	0.365
Tp positive only	20 (17.9)	4 (4.6)	0.009
Dp positive only	1 (0.9)	13 (14.9)	<0.001

Values are presented as number (%).

Tp, *Tuorhaphus puterscentias*; Dp, *Dermatophagoides pteronyssinus*.

DIFFERENT ALLERGENIC COMPONENTS OF MITES CAN ACTIVATE INNATE IMMUNE CELLS LEADING TO ALLERGIC INFLAMMATION

More than 21 allergenic components have been identified in the mites, most of which can initiate immune responses via pattern recognition receptor (Table 5).

Der p 1, a cysteine protease, can bind its specific IgE on the basophils and mast cells and can possess a very potent proteolytic activity on epithelium, resulting in a series of specific and nonspecific responses. Der p 1 can up-regulate the permeability of epithelial cells *in vivo*, most likely via degradation of tight junction proteins. In addition, a more specific response may be induced by these proteolytically active allergens. Their interaction with epithelial cells can induce the release of cytokines, such as IL-6 and IL-8, or induce fluid secretion from submucosal glands [31]. The mechanism underlying this response depends upon protease-activated receptors (PARs). PAR 2 are activated by proteolytic cleavage, which can be mediated by Der p 1 [32, 33]. Thus, Der p 1 may serve as the prototype of proteolytically active allergens.

Der p 2 and its specific IgE in the sera are highly correlated with allergic hypersensitivity in patients of asthma, atopic dermatitis and allergic rhinitis. An estimate of 79.2% of patients with asthma, wheezing and/or rhinitis has IgE antibodies to

Der p 2 [34]. Recently, the Der p 2 allergen was found to show structural homology with MD-2, suggesting that Der p 2 tends to cause targeted immune responses because of its adjuvant properties. The structure of Der p 2 provides a useful tool in the design of recombinant immunotherapeutics for the group-2 allergens [35]. Der p 2 has been demonstrated to be capable of triggering human B cell activation and Toll-like receptor 4 (TLR4) induction. Der p 2 markedly induced the expressions of several key cytokines, including IL-1 β , CXCL10, IL-8, and tumor necrosis factor (TNF)- α in B cells. Der p 2 could also enhance nuclear factor (NF)- κ B activity, indicating that Der p 2 may exert its influence through NF- κ B activation to induce the production of proinflammatory cytokines. Moreover, Der p 2 specifically up-regulated mitogen-activated protein kinase phosphatase-1 expression and activity in human B cells, which in turn resulted in p38/mitogen-activated protein kinase dephosphorylation, triggering TLR4 induction [36].

Der p 3 can induce cytokine release from human pulmonary epithelial cells. Because Der p 3 is a serine protease, it is likely to interact with the PAR 2 expressed on pulmonary epithelial cells [37]. Like trypsin, a known activator of PAR 2, Der p 3 cleaved the receptor at a specific site that exposes the tethered ligand, indicating that they do have the potential for activating PAR 2. In addition, Der p 3 can induce the release of the proinflammatory cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and eotaxin from human pulmonary epithelial cells. The production of both GM-CSF and eotaxin is increased in bronchial epithelial cells from asthmatic patients, and these cytokines play a major role in the ongoing inflammatory and structural alterations of asthma [38-42]. Eotaxin and GM-CSF promote accumulation local activation of eosinophils in the bronchial mucosa of asthmatic patients [40-43]. We also demonstrate group 3 allergen of Tp (Tyr p 3) had proteolytic activity and specific IgE in the sera from patients with airway hypersensitivity [26].

Table 4. Characteristics of mite allergy in elderly subjects with COPD

Variable	COPD (n=50)	Non-COPD (n=13)
Age (yr)	83.9 \pm 1.3	85.1 \pm 1.1
Tp allergic	19 (38.0)	0 (0)
Dp allergic	7 (14.0)	0 (0)
IL-8 (pg/mL)	63.2 \pm 12.6*	35.0 \pm 8.2

Values are presented as mean \pm standard deviation or number (%). COPD, chronic obstructive pulmonary disease; Tp, *Turophapus putrescentias*; Dp, *Dermatophagoides pteronyssinus*; IL, interleukin. * p <0.05, compared to non-COPD group.

Table 5. Major allergens of mites and their ability to activate receptors of innate immunity

Allergen	PAR	TLR	NOD-like receptor	DC-SIGN	Ref.
Der p 1	+	-	-	+	32, 33
Der p 2	-	+	-	+	36
Der p 3/Tyr P 3	+	-	-	-	26, 37

PAR, protease-activated receptor; TLR, Toll-like receptor; NOD, nucleotide-binding oligomerization domain; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.

HDM ALLERGY: DISEASE PREVENTION

Interventions to reduce allergen sensitization and to improve patients' symptoms and quality of life have obtained great achievements. However, prevention strategies for treatment of allergic diseases remain unsuccessful. Recent evidence from clinical studies has highlighted different nutritional interventions, such as dietary polyphenols vitamin D, which can impact both allergic sensitization and alleviated symptoms [44, 45]. The hygiene hypothesis suggested that sensitization may have affected the intestinal microflora composition and the immune system at an early age [46]. Distinct patterns of gut microbial composition were reported in infants with and without allergy development [47]. Supplement of probiotics is the best modality for the prevention of HDM allergy.

According to Cochrane review by Osborn and Sinn [48] in 2007, probiotics in infants for prevention of allergic diseases and food hypersensitivity was not supported by sufficient evidence. Many further investigations have been done since then. In 2013, Pyar et al. [49] indicated many diseased conditions have been observed to be due to *in vivo* microbial imbalance and the consequent conditions could be remedied by the application of appropriate probiotics. Probiotics can protect infants against life-threatening diseases by improving their bowel colonization with beneficial flora through the stimulation of the immune system. In the recent study, Vong et al. [50] demonstrated that probiotic *Lactobacillus rhamnosus* strain GG inhibits both phorbol 12-myristate 13-acetate- and *Staphylococcus aureus*-induced formation of neutrophil extracellular traps, which can prevent pathogens from damaging surrounding cells and can be used to treat chronic inflammation bowel disease. Moreover, probiotic *L. rhamnosus* strain GG could dampen reactive oxygen species production and modulate innate immunity response of the gastrointestinal tract. Therefore, whether probiotics could prevent allergic disease was reviewed.

ALLERGIC SENSITIZATION CAN BE PREVENTED BY INCREASING T REG CELLS AND SECRETORY IGA

The pathogenesis of allergic diseases is considered to be Th2-mediated inflammation. Medical scientists have hypothesized that allergic diseases might result from functional or quantitative

deficiency of Treg cells that control the Th2 immune response [51]. Wu et al. [52] reported that there were fewer Treg cells in allergic patients in comparison with nonallergic subjects. These cells could be up-regulated by using recombinant Der f 2 peptide with fungal immunomodulatory peptide fve (FIP).

It has been reported that allergen specific IgA could prevent the increased airway responsiveness and lung eosinophilia in allergen sensitized mice [53]. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice [54]. Our study also showed that the production of salivary IgA and suppression of Dp-induced airway inflammation were observed after local nasal immunotherapy with Dp2 in conjunction with FIP. We used local nasal immunotherapy with Der p 2 in conjunction with FIP [55]. From the above studies, increased IgA levels could down-regulate airway hypersensitivity, Th2-associated cytokine release and IgE production.

Administration of probiotics could stimulate the immune system and reduce inflammation on gastrointestinal diseases by increasing Treg cytokines [56]. Chiu et al. [57] reported that cytokines of Treg cells, IL-10 and TGF- β , could be up-regulated by probiotics. Therefore, it is conceivable that probiotics administration could be beneficial for allergic diseases (Fig. 3).

EFFECTS OF PROBIOTICS ON IGA PRODUCTION

Infants with allergy development have different patterns of gut microbial composition when compare to nonallergic subjects. The presence of *Clostridium difficile* indicated a high risk of developing eczema and allergic sensitization [58]. Supplemental administration can promote *in situ* inhibition of pathogens through IgA secretion of the host to reduce allergic allergen sensitization and symptoms. The level of circulating IgA was increased after probiotic intervention. Dolle et al. [59] reported that EcN, serotype O6:K5:H1 and a gram-negative bacteria strain, could up-regulate serum IgA levels in grass allergic patients. Similar report showed that consumption of probiotic products containing *Escherichia coli* strains *Lactobacillus gasseri* CECT5714 and *Lactobacillus coryniformis* CECT5711 could induce beneficial effects on immunological parameters in allergic children, causing a reduction in plasma level of IgE and an increase in the level of IgA. The probiotic dairy products increased IgA and improved the general health status of




Fig. 3. Schematic diagram of the roles of microbiota and allergen in allergen-induced allergic inflammation. IL, interleukin; TGF, transforming growth factor.

children [60].

On the other hand, probiotics failed to increase secretory IgA levels in the breast milk of these subjects during pregnancy. As Boyle et al. [61] revealed in their experiment, 250 pregnant women carrying infants at high risk of allergic diseases were prenatally treated with the probiotic *L. rhamnosus* GG (LGG) for the thirty-six week gestation until delivery. The results showed that prenatal probiotic treatment was not associated with a reduced risk of eczema or IgE-associated eczema. Furthermore, prenatal probiotic treatment was not associated with any change in cord blood immune markers, but was associated with decreased soluble CD14 and IgA levels in breast milk. The study could not provide evidence that the probiotic had beneficial effects on IgE-associated eczema. This result might be due to the low IgA level in the breast milk [62].

EFFECTS OF PROBIOTICS ON TREG CELLS

Yoshida et al. [63] used Balb/c mice which were administered *Lactobacillus plantarum* NRIC0380 orally, and found that the increased proliferation of Treg cells was obtained from the mice that had been fed NRIC0380. The Treg cells obtained from the mice exposed to NRIC0380 significantly inhibited the IgE production and active cutaneous anaphylaxis reaction when transferred into another mouse that was subsequently immunized with the crude bovine β -lactoglobulin. Furthermore, the Treg cells also significantly suppressed the passive cutaneous anaphylaxis reaction when they were cotransferred with the IgE antibody into another mouse. In ovalbumin (OVA) immunized mice model, *L. rhamnosus* (Lcr35) treatment of Ha-Jung Kim et

al. [64]. led to an increase in the number of CD4⁺ CD25⁺ Foxp3⁺ Treg cells in the mesenteric lymph nodes of allergic march in OVA sensitized mice. Similar finding of Lcr35 treatment was observed in the report of Jang et al. [65]. In their experiment, Balb/c mice were administered Lcr35 a week before first sensitization, and airway hyperresponsiveness, total IgE production, pulmonary eosinophilic inflammation, and splenic lymphocyte proliferation were suppressed after Lcr35 treatment. Th1 (interferon [IFN]- γ) and Th2 (IL-4, IL-5, and IL-13) cytokines in the serum were also suppressed, and the percentage of Treg cells in the spleen was significantly increased in the Lcr35 treated group. Anti-CD25 mAb administration abolished the protective effects of Lcr35, indicating that CD4⁺ CD25⁺Foxp3⁺ Treg cells are essential in mediating the activity of Lcr35. In the above animal model of allergic diseases, probiotics could increase Treg cells and down-regulate Th2 cell cytokine and IgE production.

BENEFIT OF PROBIOTIC ON THE ALLERGIC SYMPTOMS REMAINS INCONCLUSIVE

We reviewed current publications in the recent four years. Studies of probiotics on allergic respiratory symptoms are still inconclusive. A few studies conducted in children and adults with allergic rhinitis had encouraging results showing that allergic rhinitis symptoms could be reduced. Effective reports were conducted in several double-blind placebo controlled studies, which demonstrated reduced allergic rhinitis symptoms and down-regulated Th2 cells activation following treatment with *Lactobacillus paracasei* NCC2461, *Lactobacillus salivarius* PM-A0006, *Lactobacillus johnsonii* EM1 and *L. paracasei* ST11 in children or adolescents with allergic rhinitis (Table 6) [66-69]. However, some studies conducted in adults were not effective in reducing the symptoms. Noneffective reports were conducted in the studies, which included the failure to relieve allergic symptoms in children or adults given *L. paracasei*, *Bifidobacterium longum* (BL999), *L. rhamnosus* (LPR), *Lactobacillus casei* Shirota, *L. paracasei ssp paracasei* F19 (Table 7) [70-73]. These different outcomes could be due to different strains of probiotics used. To assure the effect of probiotics on allergic inflammation, the optimal dosage, probiotic strains, duration of intervention and patients' subpopulations were important.

DIFFERENT STRAINS OF PROBIOTICS HAVE DIFFERENT FUNCTIONS

Since Human breast milk contained a wide spectrum of indigestible nutrients that are not utilized by the infants but exert biomarker functions on establishment of indigenous microbiota, they might serve as natural prebiotics. The best examples are human milk oligosaccharides, which serve as growth stimulants for some colonic bacteria in breast milk as well as in breast-fed infants' gastro intestinal tract. *Bifidobacteria* are the predominant components of the intestinal flora in breast-fed infants. These bacteria groups play a vital role in maintaining the gut health and protecting the infants from pathogen infections, and contribute to maturation of the systemic immunity.

A total of 18 strains of bacteria strain were identified from human breast milk. We found that *Bifidobacterium adolescentis* DB-2458 and *Bifidobacterium longum* subsp. infantis GB-1496 exhibited a strong immunomodulatory ability to increase Th1-associated

cytokine induction and to lower Th2-associated cytokine production. Besides these two strains, *B. longum* HB-762 exerted the most excellent anti-inflammatory capacities according to high levels of IL-10 and TGF- β cytokine inductions [57]. Similar finding was found in *L. casei* MYL01, which induced the production of IL-10 from HepG2 cells [74].

Eleven *Bifidobacterium* strains isolated from the feces of newborn babies were screened for their ability to induce cytokine production of human peripheral blood mononuclear cells. Among the eleven viable strains, *L. gasseri* AI-88 was the strongest inducer of IFN- γ and IL-12p70 production. However, after heat treatments, its stimulatory ability was attenuated. Heat-killed *Enterococcus faecalis* YM-73 and *L. salivarius* AP-32 strains showed an enhanced stimulation of IFN- γ and IL-12p70 secretion and a coincidental decrease in IL-13 production. The adhesion of lactic acid bacteria to Caco-2 cells decreased with the increase in temperature. However, heat exposure did not influence immunomodulatory activity. As temperature rose, roughness and unevenness of

Table 6. Comparison of prior studies showing effective probiotics to allergic rhinitis

Year	Probiotics strain	Dosage	Subjects/model	Ref.
2014	Either <i>Lactobacillus paracasei</i> NCC2461 or a blend (1:3) of <i>Lactobacillus acidophilus</i> ATCC SD5221 and <i>Bifidobacterium lactis</i> ATCC SD5219	Powder sachets contained maltodextrin and probiotics ($\approx 10^{10}$ CFU each), either <i>L. paracasei</i> NCC2461 or a blend (1:3) of <i>L. acidophilus</i> <i>B. lactis</i>	31 Adults age between 18–35 yr	66
2012	<i>Lactobacillus salivarius</i> PM-A0006	4×10^9 CFU/g	199 Children age between 6–12 yr	67
2012	<i>Lactobacillus johnsonii</i> EM1	Levocetirizine (5 mg) combined with LJ EM1 (1×10^{10} CFU/capsule)	63 Children age between 7–12 yr	68
2011	<i>Lactobacillus paracasei</i> ST11	$4\text{--}9 \times 10^{10}$ CFU/day/subject	31 Adults age between 18–35 yr	69

CFU, colony-forming unit.

Table 7. Comparison of prior studies showing noneffective probiotics to allergic rhinitis

Year	Probiotics strain	Dosage	Subjects/model	Ref
2014	<i>Lactobacillus paracasei</i>	Levocetirizine plus LP (5×10^9 CFU/capsule)	60 Children age between 6–13 yr	70
2014	<i>Bifidobacterium longum</i> (BL999) and <i>Lactobacillus rhamnosus</i> (LPR)	<i>B. longum</i> BL999 1×10^7 CFU/g and <i>L. rhamnosus</i> LPR 2×10^7 CFU/g	220 Infants	71
2013	<i>Lactobacillus casei</i> Shirota	65-mL fermented milk drink containing <i>L. casei</i> Shirota 1×10^9 CFU/mL	60 Adults age >16 yr	72
2013	<i>L. paracasei</i> ssp <i>paracasei</i> F19	1×10^8 CFU daily	179 Infants	73

CFU, colony-forming unit.

bacterial cell surfaces increased significantly. The results indicated that heat-killed *E. faecalis* YM-73 and *L. salivarius* AP-32 possessed immunomodulatory ability by increasing Th1-associated cytokines and reducing Th2-associated cytokines, switching the immune response from a Th2 toward a Th1 response [75].

In clinical studies, four strains of probiotics, *B. adolescentis* DB-2458, *B. longum subsp. Infantis* GB-1496, *B. longum* HB-762, and *Lactobacillus reuteri* GL-44, were used to evaluate their effects on the peripheral mononuclear cells derived from eight HDM allergic patients. The results demonstrated that Th2 associated cytokines, IL-5 and IL-13, and proinflammatory cytokines, IL-6 and TNF- α , were both decreased. In the presence of Dp crude extract, probiotics–DB-2458, GB-1496, and HB-762–could improve the balance of Th1/Th2 and reduce the production of inflammatory cytokines from allergic subjects.

In the above studies, probiotics isolated from breast milk and infant feces could up-regulate Th1 associated cytokine and reduce Th2 associated cytokine to prevent allergy development. Both freshly isolated and heat-killed bacilli were similarly effective in the *in vitro* study.

CONCLUSION

Dust mite allergy affects approximately 40% of the industrial global population. It could be found in the living and working environments. There are many types of dust mite species and prevalence of different mite allergy varies with patients' age groups. Major mechanism of allergic response is Th2 cytokine production, which would induce the production of IgE antibodies by B cells. When the subjects are exposed to allergens again, allergic reactions would be induced. Since using drugs such as steroid, antihistamine, etc. are not successful. Therefore, prevention of allergic development is more important than treatment. Probiotics may provide an alternative modality to prevent allergy developments and to achieve beneficial effects by increasing the number of Treg cells and by enhancing IgA production from B cells. Although the effect of probiotics is still inconclusive on allergic symptoms, in order to achieve successful interventions, choosing correct therapeutic doses and strains of microbiota could be critical to achieve optimal therapeutic effects.

ACKNOWLEDGEMENTS

We give special thanks to Catherine Tsai for editing grammar.

REFERENCES

1. Arlian LG, Morgan MS. Biology, ecology, and prevalence of dust mites. *Immunol Allergy Clin North Am* 2003;23:443-68.
2. Fernandez-Caldas E, Iraola V, Carnes J. Molecular and biochemical properties of storage mites (except *Blomia* species). *Protein Pept Lett* 2007;14:954-9.
3. Thomas WR, Smith WA, Hales BJ. The allergenic specificities of the house dust mite. *Chang Gung Med J* 2004;27:563-9.
4. Tsai JJ, Wu HH, Shen HD, Hsu EL, Wang SR. Sensitization to *Blomia tropicalis* among asthmatic patients in Taiwan. *Int Arch Allergy Immunol* 1998;115:144-9.
5. Tsai JJ, Yi FC, Chua KY, Liu YH, Lee BW, Cheong N. Identification of the major allergenic components in *Blomia tropicalis* and the relevance of the specific IgE in asthmatic patients. *Ann Allergy Asthma Immunol* 2003;91:485-9.
6. Tsai JJ, Shen HD, Chua KY. Purification of group 2 Dermatophagoides pteronyssinus allergen and prevalence of its specific IgE in asthmatics. *Int Arch Allergy Immunol* 2000;121:205-10.
7. Liao EC, Lin YH, Tsai JJ. Detection of group 2 Dermatophagoides pteronyssinus allergen for environmental monitoring of dust mite infestation. *Biosci Trends* 2013;7:82-8.
8. Tsai JJ, Bau IJ, Chen HT, Lin YT, Wang GJ. A novel nanostructured biosensor for the detection of the dust mite antigen Der p2. *Int J Nanomedicine* 2011;6:1201-8.
9. Lambrecht BN. Dendritic cells and the regulation of the allergic immune response. *Allergy* 2005;60:271-82.
10. Novak N, Haberstick J, Geiger E, Bieber T. Dendritic cells in allergy. *Allergy* 1999;54:792-803.
11. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. *J Exp Med* 2001;193:51-60.
12. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. *Lancet* 2010;376:835-43.
13. Tsai JJ, Ho CY, Wang SR. Relationship between nasal resistance and airway hyperreactivity following nasal provocation with Dermatophagoides pteronyssinus in allergic rhinitis. *Int Arch Allergy Immunol* 1995;106:286-90.

14. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, Gutierrez-Ramos JC, Ellis R, Inman MD, Jordana M. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. *Am J Respir Crit Care Med* 2004;169:378-85.
15. Tomlinson KL, Davies GC, Sutton DJ, Palframan RT. Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite. *PLoS One* 2010;5:e13136.
16. Barnes PJ. Pathophysiology of allergic inflammation. *Immunol Rev* 2011;242:31-50.
17. Sánchez-Machin I, Glez-Paloma Poza R, Iglesias-Souto J, Iraola V, Matheu V. Oral mite anaphylaxis. *Allergy* 2010;65:1345-7.
18. Arlian LG, Geis DP, Vyszynski-Moher DL, Bernstein IL, Gallagher JS. Antigenic and allergenic properties of the storage mite *Tyrophagus putrescentiae*. *J Allergy Clin Immunol* 1984;74:166-71.
19. Arlian LG, Vyszynski-Moher DL, Johansson SG, van Hage-Hamsten M. Allergenic characterization of *Tyrophagus putrescentiae* using sera from occupationally exposed farmers. *Ann Allergy Asthma Immunol* 1997;79:525-9.
20. van Hage-Hamsten M, Johansson E. Clinical and immunologic aspects of storage mite allergy. *Allergy* 1998;53(48 Suppl):49-53.
21. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. *Trends Mol Med* 2010;16:321-8.
22. Henszel L, Kuzna-Grygiel W. House dust mites in the etiology of allergic diseases. *Ann Acad Med Stetin* 2006;52:123-7.
23. Liao EC, Ho CM, Yin SC, Tsai JJ. Immune responses to tyrophagus putrescentiae-induced airway inflammation in mice. *J Invest Allergol Clin Immunol* 2013;23:20-9.
24. Chang YC, Hsieh KH. The study of house dust mites in Taiwan. *Ann Allergy* 1989;62:101-6.
25. Kam KL, Hsieh KH. Comparison of three in vitro assays for serum IgE with skin testing in asthmatic children. *Ann Allergy* 1994;73:329-36.
26. Liao EC, Hsu EL, Tsai JJ, Ho CM. Immunologic characterization and allergenicity of recombinant Tyr p 3 allergen from the storage mite *Tyrophagus putrescentiae*. *Int Arch Allergy Immunol* 2009;150:15-24.
27. Vidal C, Boquete O, Gude F, Rey J, Meijide LM, Fernandez-Merino MC, González-Quintela A. High prevalence of storage mite sensitization in a general adult population. *Allergy* 2004;59:401-5.
28. Munhbayarlah S, Park JW, Ko SH, Ree HI, Hong CS. Identification of *Tyrophagus putrescentiae* allergens and evaluation of cross-reactivity with *Dermatophagoides pteronyssinus*. *Yonsei Med J* 1998;39:109-15.
29. Liao EC, Ho CM, Tsai JJ. Prevalence of *Tyrophagus putrescentiae* hypersensitivity in subjects over 70 years of age in a veterans' nursing home in Taiwan. *Int Arch Allergy Immunol* 2010;152:368-77.
30. Tsai JJ, Liao EC, Hsu JY, Lee WJ, Lai YK. The differences of eosinophil- and neutrophil-related inflammation in elderly allergic and non-allergic chronic obstructive pulmonary disease. *J Asthma* 2010;47:1040-4.
31. Cho HJ, Lee HJ, Kim SC, Kim K, Kim YS, Kim CH, Lee JG, Yoon JH, Choi JY. Protease-activated receptor 2-dependent fluid secretion from airway submucosal glands by house dust mite extract. *J Allergy Clin Immunol* 2012;129:529-35, 535.e1-5.
32. Asokanathan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. *J Immunol* 2002;168:3577-85.
33. Asokanathan N, Graham PT, Stewart DJ, Bakker AJ, Eidne KA, Thompson PJ, Stewart GA. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. *J Immunol* 2002;169:4572-8.
34. Trombone AP, Tobias KR, Ferriani VP, Schuurman J, Aalberse RC, Smith AM, Chapman MD, Arruda LK. Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. *Clin Exp Allergy* 2002;32:1323-8.
35. Abreu MT, Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. *J Pediatr* 2004;144:421-9.
36. Tsai JJ, Liu SH, Yin SC, Yang CN, Hsu HS, Chen WB, Liao EC, Lee WJ, Pan HC, Sheu ML. Mite allergen Der-p2 triggers human B lymphocyte activation and Toll-like receptor-4 induction. *PLoS One* 2011;6:e23249.
37. D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. *J Histochem Cytochem* 1998;46:157-64.
38. Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. *Clin Exp Immunol* 1998;114:137-46.
39. Ackerman V, Marini M, Vittori E, Bellini A, Vassali G, Mattoli S. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients. Relationship to atopic status, symptoms, and level of airway hyperresponsiveness. *Chest* 1994;105:687-96.
40. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ,

- Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. *Eur J Immunol* 1997;27:3507-16.
41. Soloperto M, Mattoso VL, Fasoli A, Mattoli S. A bronchial epithelial cell-derived factor in asthma that promotes eosinophil activation and survival as GM-CSF. *Am J Physiol* 1991;260(6 Pt 1):L530-8.
42. Mattoli S, Stacey MA, Sun G, Bellini A, Marini M. Eotaxin expression and eosinophilic inflammation in asthma. *Biochem Biophys Res Commun* 1997;236:299-301.
43. Seminario MC, Gleich GJ. The role of eosinophils in the pathogenesis of asthma. *Curr Opin Immunol* 1994;6:860-4.
44. Akan A, Azkur D, Ginis T, Toyran M, Kaya A, Vezir E, Ozcan C, Ginis Z, Kocabas CN. Vitamin D level in children is correlated with severity of atopic dermatitis but only in patients with allergic sensitizations. *Pediatr Dermatol* 2013;30:359-63.
45. Zuercher AW, Weiss M, Holvoet S, Moser M, Moussu H, van Overtvelt L, Horiot S, Moingeon P, Nutten S, Prioult G, Singh A, Mercenier A. *Lactococcus lactis* NCC 2287 alleviates food allergic manifestations in sensitized mice by reducing IL-13 expression specifically in the ileum. *Clin Dev Immunol* 2012;2012:485750.
46. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. *Altern Med Rev* 2004;9:180-97.
47. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. *Clin Exp Allergy* 2014;44:842-50.
48. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. *Cochrane Database Syst Rev* 2007;(4):CD006475.
49. Pyar H, Liong MT, Peh KK. Recent advances in probiotics and biomedical applications. *J Med Sci* 2013;13:601-14.
50. Vong L, Lorentz RJ, Assa A, Glogauer M, Sherman PM. Probiotic *Lactobacillus rhamnosus* inhibits the formation of neutrophil extracellular traps. *J Immunol* 2014;192:1870-7.
51. Hinz D, Simon JC, Maier-Simon C, Milkova L, Roder S, Sack U, Borte M, Lehmann I, Herberth G. Reduced maternal regulatory T cell numbers and increased T helper type 2 cytokine production are associated with elevated levels of immunoglobulin E in cord blood. *Clin Exp Allergy* 2010;40:419-26.
52. Wu CC, Liao EC, Lee MF, Tsai JJ. Augmentation of regulatory T cells in allergic individuals by recombinant Der f 2 peptide with fungal immunomodulatory peptide fve. *Ann Allergy Asthma Immunol* 2009;102:216-22.
53. Schwarze J, Cieslewicz G, Joetham A, Sun LK, Sun WN, Chang TW, Hamelmann E, Gelfand EW. Antigen-specific immunoglobulin-A prevents increased airway responsiveness and lung eosinophilia after airway challenge in sensitized mice. *Am J Respir Crit Care Med* 1998;158:519-25.
54. Takabayashi K, Libet L, Chisholm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. *J Immunol* 2003;170:3898-905.
55. Liu YH, Tsai JJ. Production of salivary immunoglobulin A and suppression of *Dermatophagoides pteronyssinus*-induced airway inflammation by local nasal immunotherapy. *Int Arch Allergy Immunol* 2005;138:161-8.
56. Chiu YH, Lin SL, Tsai JJ, Lin MY. Probiotic actions on diseases: implications for therapeutic treatments. *Food Funct* 2014;5:625-4.
57. Chiu YH, Tsai JJ, Linc SL, Chotirowsakina C, Lina MY. Characterisation of bifidobacteria with immunomodulatory properties isolated from human breast milk. *J Funct Food* 2014;7:700-8.
58. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. *Gut* 2007;56:661-7.
59. Dolle S, Berg J, Rasche C, Worm M. Tolerability and clinical outcome of coseasonal treatment with *Escherichia coli* strain Nissle 1917 in grass pollen-allergic subjects. *Int Arch Allergy Immunol* 2014;163:29-35.
60. Martinez-Canavate A, Sierra S, Lara-Villoslada F, Romero J, Maldonado J, Boza J, Xaus J, Olivares M. A probiotic dairy product containing *L. gasseri* CECT5714 and *L. coryniformis* CECT5711 induces immunological changes in children suffering from allergy. *Pediatr Allergy Immunol* 2009;20:592-600.
61. Boyle RJ, Ismail IH, Kivivuori S, Licciardi PV, Robins-Browne RM, Mah LJ, Axelrad C, Moore S, Donath S, Carlin JB, Lahtinen SJ, Tang ML. *Lactobacillus GG* treatment during pregnancy for the prevention of eczema: a randomized controlled trial. *Allergy* 2011;66:509-16.
62. Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G. Probiotics in the prevention of eczema: a randomised controlled trial. *Arch Dis Child* 2014;99:1014-9.
63. Yoshida T, Fujiwara W, Enomoto M, Nakayama S, Matsuda H, Sugiyama H, Shimojoh M, Okada S, Hattori M. An increased number of CD4+CD25+ cells induced by an oral administration of *Lactobacillus plantarum* NRIC0380 are involved in anti-allergic

- activity. *Int Arch Allergy Immunol* 2013;162:283-9.
64. Kim HJ, Kim YJ, Kang MJ, Seo JH, Kim HY, Jeong SK, Lee SH, Kim JM, Hong SJ. A novel mouse model of atopic dermatitis with epicutaneous allergen sensitization and the effect of *Lactobacillus rhamnosus*. *Exp Dermatol* 2012;21:672-5.
65. Jang SO, Kim HJ, Kim YJ, Kang MJ, Kwon JW, Seo JH, Kim HY, Kim BJ, Yu J, Hong SJ. Asthma prevention by *Lactobacillus Rhamnosus* in a mouse model is associated with CD4(+)CD25(+)Foxp3(+) T cells. *Allergy Asthma Immunol Res* 2012;4:150-6.
66. Lue KH, Sun HL, Lu KH, Ku MS, Sheu JN, Chan CH, Wang YH. A trial of adding *Lactobacillus johnsonii* EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. *Int J Pediatr Otorhinolaryngol* 2012;76:994-1001.
67. Lin TY, Chen CJ, Chen LK, Wen SH, Jan RH. Effect of probiotics on allergic rhinitis in Df, Dp or dust-sensitive children: a randomized double blind controlled trial. *Indian Pediatr* 2013;50:209-13.
68. Wassenberg J, Nutten S, Audran R, Barbier N, Aubert V, Moulin J, Mercenier A, Spertini F. Effect of *Lactobacillus paracasei* ST11 on a nasal provocation test with grass pollen in allergic rhinitis. *Clin Exp Allergy* 2011;41:565-73.
69. Schabussova I, Hufnagl K, Tang ML, Hoflehner E, Wagner A, Loupal G, Nutten S, Zuercher A, Mercenier A, Wiedermann U. Perinatal maternal administration of *Lactobacillus paracasei* NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy. *PLoS One* 2012;7:e40271.
70. Lin WY, Fu LS, Lin HK, Shen CY, Chen YJ. Evaluation of the effect of *Lactobacillus paracasei* (HFA00232) in children (6-13 years old) with perennial allergic rhinitis: a 12-week, double-blind, randomized, placebo-controlled study. *Pediatr Neonatol* 2014;55:181-8.
71. Loo EX, Llanora GV, Lu Q, Aw MM, Lee BW, Shek LP. Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up. *Int Arch Allergy Immunol* 2014;163:25-8.
72. West CE, Hammarström ML, Hernell O. Probiotics in primary prevention of allergic disease: follow-up at 8-9 years of age. *Allergy* 2013;68:1015-20.
73. Ivory K, Wilson AM, Sankaran P, Westwood M, McCarville J, Brockwell C, Clark A, Dainty JR, Zuidmeer-Jongejan L, Nicoletti C. Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial. *PLoS One* 2013;8:e78650.
74. Chiu YH, Tsai JJ, Lin SL, Lin MY. *Lactobacillus casei* MYL01 modulates the proinflammatory state induced by ethanol in an in vitro model. *J Dairy Sci* 2014;97:2009-16.
75. Ou CC, Lin SL, Tsai JJ, Lin MY. Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. *J Food Sci* 2011;76:M260-7.